CY1118091T1 - Ανοσολογικως χρησιμα αλατα αργινινης - Google Patents

Ανοσολογικως χρησιμα αλατα αργινινης

Info

Publication number
CY1118091T1
CY1118091T1 CY20161101006T CY161101006T CY1118091T1 CY 1118091 T1 CY1118091 T1 CY 1118091T1 CY 20161101006 T CY20161101006 T CY 20161101006T CY 161101006 T CY161101006 T CY 161101006T CY 1118091 T1 CY1118091 T1 CY 1118091T1
Authority
CY
Cyprus
Prior art keywords
immunology
useful
arginine salts
arginine
salts
Prior art date
Application number
CY20161101006T
Other languages
English (en)
Inventor
Stephanie Kay Dodd
Siddartha Jain
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1118091T1 publication Critical patent/CY1118091T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η εφεύρεση ανήκει στο πεδίο των μορφών άλατος μιας ανοσοενισχυτικής ένωσης και την διαμόρφωσή τους για in vivo χρήση.
CY20161101006T 2012-03-07 2016-10-10 Ανοσολογικως χρησιμα αλατα αργινινης CY1118091T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261608011P 2012-03-07 2012-03-07
PCT/EP2013/054548 WO2013131985A1 (en) 2012-03-07 2013-03-07 Immunologically useful arginine salts

Publications (1)

Publication Number Publication Date
CY1118091T1 true CY1118091T1 (el) 2017-06-28

Family

ID=47843276

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101006T CY1118091T1 (el) 2012-03-07 2016-10-10 Ανοσολογικως χρησιμα αλατα αργινινης

Country Status (18)

Country Link
US (1) US9320748B2 (el)
EP (1) EP2822947B1 (el)
JP (1) JP6325986B2 (el)
CN (1) CN104203946B (el)
AU (1) AU2013229466A1 (el)
CA (1) CA2865759C (el)
CY (1) CY1118091T1 (el)
DK (1) DK2822947T3 (el)
ES (1) ES2597755T3 (el)
HR (1) HRP20161354T1 (el)
HU (1) HUE030175T2 (el)
LT (1) LT2822947T (el)
MX (1) MX346678B (el)
PL (1) PL2822947T3 (el)
PT (1) PT2822947T (el)
RU (1) RU2014140336A (el)
SI (1) SI2822947T1 (el)
WO (1) WO2013131985A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2772916C (en) 2009-09-02 2019-01-15 Novartis Ag Immunogenic compositions including tlr activity modulators
EA201390341A1 (ru) 2010-09-01 2013-08-30 Новартис Аг Адсорбция иммунопотенциаторов на нерастворимых солях металлов
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
JP6894237B2 (ja) 2014-03-26 2021-06-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 変異体ブドウ球菌抗原
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
WO2021178306A1 (en) * 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
US20220280482A1 (en) * 2021-03-06 2022-09-08 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
EP0967279B1 (en) 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
DE69529219T2 (de) 1994-07-01 2003-11-06 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Helicobacter proteine und impstoffe
WO1997025429A1 (en) 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
NZ546711A (en) 2001-12-12 2008-06-30 Chiron Srl Immunisation against chlamydia trachomatis
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
MXPA05013260A (es) 2003-06-26 2006-03-09 Chiron Corp Composiciones inmunogenicas para chlamydia trachomatis.
WO2005084306A2 (en) 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
EP1858919B1 (en) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
EP1858920B1 (en) 2005-02-18 2016-02-03 GlaxoSmithKline Biologicals SA Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
JP2008544745A (ja) 2005-05-12 2008-12-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓのための免疫原性組成物
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2006341122B2 (en) 2005-12-22 2013-08-22 Novartis Vaccines And Diagnostics, Srl. Chlamydial antigens
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
PL2200642T3 (pl) 2007-10-19 2012-09-28 Novartis Ag Preparaty szczepionek meningokokowych
US8679505B2 (en) 2009-04-14 2014-03-25 Novartis Ag Compositions for immunising against Staphylococcus aureus
EP2437777B1 (en) 2009-06-01 2014-09-17 Novartis AG COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES
CA2765112A1 (en) * 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
CA2772916C (en) 2009-09-02 2019-01-15 Novartis Ag Immunogenic compositions including tlr activity modulators
JO3257B1 (ar) * 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
EA201390341A1 (ru) 2010-09-01 2013-08-30 Новартис Аг Адсорбция иммунопотенциаторов на нерастворимых солях металлов
WO2012103421A1 (en) 2011-01-27 2012-08-02 Novartis Ag Adjuvant nanoemulsions with crystallisation inhibitors
BR112014004782A2 (pt) * 2011-09-01 2017-03-21 Novartis Ag formulações adjuvantes de antígenos de staphylococcus aureus

Also Published As

Publication number Publication date
CN104203946A (zh) 2014-12-10
CN104203946B (zh) 2017-03-22
CA2865759A1 (en) 2013-09-12
EP2822947B1 (en) 2016-08-03
AU2013229466A1 (en) 2014-09-04
JP6325986B2 (ja) 2018-05-16
HUE030175T2 (en) 2017-04-28
HRP20161354T1 (hr) 2016-12-02
DK2822947T3 (en) 2016-09-19
MX2014010423A (es) 2014-09-22
JP2015511957A (ja) 2015-04-23
EP2822947A1 (en) 2015-01-14
MX346678B (es) 2017-03-29
PT2822947T (pt) 2016-09-26
PL2822947T3 (pl) 2017-01-31
WO2013131985A1 (en) 2013-09-12
RU2014140336A (ru) 2016-04-27
US20150125475A1 (en) 2015-05-07
US9320748B2 (en) 2016-04-26
ES2597755T3 (es) 2017-01-20
CA2865759C (en) 2020-07-21
LT2822947T (lt) 2016-10-10
SI2822947T1 (sl) 2016-10-28

Similar Documents

Publication Publication Date Title
CY1118091T1 (el) Ανοσολογικως χρησιμα αλατα αργινινης
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
CY1122222T1 (el) Συνθεση βορονικων αλατων και χρησεις αυτων
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
CR20150507A (es) Inhibidores de histona desmetilasas
BR112013023241A2 (pt) melhorias para entidades biológicas imobilizadas
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
CO7151511A2 (es) Derivado de cicloalcano
BR112013029785A2 (pt) dispositivo de varredura para interferometria de coerência baixa
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
TR201908418T4 (tr) Sürdürülebilir immünoterapi için yöntem ve kompozisyonlar.
UY34406A (es) Compuestos y métodos para mejorar la respuesta inmune innata
TWD158887S (zh) 粉餅盒
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112015012907A2 (pt) composição de cuidado pessoal
BR112015029858A2 (pt) toalha sanitária
CR20120517A (es) Piridinas sustituidas que tienen acción herbicida
CO7350653A2 (es) Retinoides y uso de los mismos
EA201201667A1 (ru) Способ получения l-аргининовой соли периндоприла
FR3005367B1 (fr) Detecteur compact de presence humaine
BR112015024351A2 (pt) formulação de l-5-metiltetrahidrofolato de cálcio amorfo (l-5-mthf-ca)
UY34005A (es) Gen insecticida variante de axmi115 y métodos para utilizarlo
BR112014000256A2 (pt) formulação de microemulsões transparentes e nutritivas
BR112014033013A2 (pt) uso de tiossulfato para potenciar o efeito anti-patogênico de lactobacillus